Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac allograft vasculopathy--a changing perspective.

M E Russell1

  • 1Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02215, USA.

Zeitschrift Fur Kardiologie
|January 11, 2001
PubMed
Summary

Cardiac allograft vasculopathy (CAV) is a complex condition involving multiple factors. Future therapies aim to modify both the donor organ and the recipient

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Investigation into the Cinematograph and Deterioration in Behaviour.

Mental health (London)·2017
Same author

Effect of soccer footwear on landing mechanics.

Scandinavian journal of medicine & science in sports·2012
Same author

Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial.

Lancet (London, England)·2011
Same author

CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis.

The American journal of pathology·2001
Same author

1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors.

Bioorganic & medicinal chemistry letters·2000
Same author

Attenuated cardiac allograft vasculopathy in mice with targeted deletion of the transcription factor STAT4.

Circulation·2000

Area of Science:

  • Cardiology
  • Immunology
  • Transplantation Science

Background:

  • Cardiac allograft vasculopathy (CAV) is a significant long-term complication after heart transplantation.
  • It is characterized by diffuse intimal thickening and graft dysfunction.

Purpose of the Study:

  • To elucidate the multifactorial nature of Cardiac allograft vasculopathy (CAV).
  • To identify key therapeutic targets for preventing and treating CAV.

Main Methods:

  • Review of recent clinical and basic studies on CAV.
  • Analysis of contributing factors including fibrosis, arteritis, and atheroma.

Main Results:

  • CAV is regulated by interacting forces at different stages of the disease process.
  • Three primary forms of vasculopathy—fibrosis, arteritis, and atheroma—contribute to graft vascular disease.

Conclusions:

  • Current CAV therapies must address both alloantigen-dependent and independent factors.
  • Future strategies should involve donor manipulation (reducing antigenicity/ischemia) and recipient manipulation (donor-specific immune response modulation).

Related Experiment Videos